Semaglutide Research Peptide

Research Overview

Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist engineered from native human GLP-1 with two key modifications: an aminoisobutyric acid (Aib) substitution at position 8 that confers DPP-4 resistance, and a C18 fatty diacid side chain attached via a γ-glutamic acid spacer to lysine-26 that enables reversible albumin binding. Together these changes extend the molecule's plasma half-life from ~2 minutes (native GLP-1) to roughly 7 days, allowing once-weekly research dosing protocols. As one of the most influential metabolic peptides of the past decade, Semaglutide is studied for its potent activation of the GLP-1 receptor across pancreatic β-cells (glucose-dependent insulin secretion), the central nervous system (satiety signaling via hypothalamic POMC and arcuate nucleus circuits), the gastrointestinal tract (delayed gastric emptying), and cardiovascular tissues. Researchers leverage Semaglutide to model glucose homeostasis, weight regulation, appetite neuroscience, lipid metabolism and cardio-metabolic risk. Its exceptional pharmacokinetic profile and consistent receptor engagement also make it the benchmark molecule against which newer multi-receptor agonists like Tirzepatide, Retatrutide, Mazdutide and Survodutide are compared in incretin research.

CAS Number

910463-68-2

Molecular Formula

C187H291N45O59

Molar Mass

4113.58 g/mol

Molecular Sequence

HAib-EGTFTSDVSSYLEGQAAK(γE-C18 diacid)EFIAWLVRGRG